More than two years after its approval in Europe, PTC Therapeutics' gene therapy for rare genetic disorder AADC deficiency will soon be made available to patients in the US. The FDA has approved PTC's ...

In a potentially pivotal trial, PTC Therapeutics' experimental therapy for Huntington's disease (HD) met its primary endpoint, but questions about the data have raised doubts about the company's ...

Most Americans agree: This economy stinks. Practically every consumer sentiment survey and political poll points to that theme. People feel like their dollars aren’t stretching as far as before, and ...

PTC Industries (PTCIL)’s Q2FY26 EBITDA recovered to INR 257mn (+21% YoY), after a dismal Q1, as we believe TARC EBITDA losses would have reduced and ATL performance has improved. EBITDA margin, at ...

PTC is selling off its IoT businesses, Kepware and ThingWorx, in order to hone its focus on SaaS and AI, according to CEO Neil Barua, as the conglomerate announced a sale of the operations to asset ...

Goldman Sachs flags PTC Industries as a key APAC pick driven by titanium and aerospace growth catalysts. Goldman Sachs has added PTC Industries in its latest APAC Conviction List. The global brokerge ...

PTC Inc. (NASDAQ:PTC) reported its financial results for the third quarter of 2025, showcasing strong growth in annual recurring revenue (ARR) and notable advancements in AI-driven product innovation.

PTC has evolved into an SaaS-driven industrial software leader with improved profitability, higher margins, and a stronger competitive moat. Growth has been heavily acquisition-driven, raising ...

The FDA rejected PTC Therapeutics' NDA for vatiquinone, citing insufficient efficacy evidence and requiring an additional study for resubmission. The MOVE-FA trial, a Phase II/III study, failed to ...

PTC Inc. (NASDAQ:PTC) reported its Q3 2025 earnings, showcasing a strong performance that surpassed analyst expectations. The company achieved an earnings per share (EPS) of $1.64, significantly ...